Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lung Neoplasms 20Ovarian Neoplasms 15Carcinoma, Non-Small-Cell Lung 15Fallopian Tube Neoplasms 13Colorectal Neoplasms 10Pancreatic Neoplasms 9Carcinoma, Hepatocellular 9Melanoma 8Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Breast Neoplasms 6Urinary Bladder Neoplasms 5Prostatic Neoplasms 5Neoplasm Metastasis 5Mycosis Fungoides 5Lymphoma, T-Cell, Cutaneous 5Carcinoma, Renal Cell 5Neoplasms 4Uterine Cervical Neoplasms 3Sezary Syndrome 3Sarcoma 3Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, T-Cell 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Glioblastoma 3Endometrial Neoplasms 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3

Interventions

Surveys and Questionnaires 6Standard of Care 6Blood Specimen Collection 6BNT162 Vaccine 5Hydroxychloroquine 4Surgical Procedures, Operative 3Specimen Handling 3Practice Guidelines as Topic 3COVID-19 Vaccines 32019-nCoV Vaccine mRNA-1273 3tocilizumab 2sotrovimab 2Pandemic Preparedness 2CVnCoV COVID-19 vaccine 2Azithromycin 2sinovac COVID-19 vaccine 1selinexor 1remdesivir 1ogalvibart 1monalizumab 1lenzilumab 1heterologous prime boost COVID-19 vaccination 1crexavibart 1cilgavimab and tixagevimab drug combination 1ciclesonide 1avdoralimab 1XAV-19 1Therapeutics 1Telemedicine 1Sperm Count 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × COVID-19 × Immunoglobulin G × Clear all
NCT04361552 2020-06-18

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Emory University

Phase 3 Withdrawn
Genitourinary

COVID-19, Coronary Artery Disease, Diabetes Mellitus, Kidney Failure, Chronic, Neoplasms, Stroke, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡